世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

Radioligand Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027Segmented By Indication (Prostate Cancer, Neuroendocrine Tumor, Others), By Product (Lutathera, Zytiga, Xtandi, Xofigo), By Biomarker (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor), By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others), By Company, and By Region


The global radioligand therapy market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors, including the rising incidence of various types of cancer... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
TechSci Research
テックサイリサーチ
2023年6月1日 US$4,900
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
119 英語

 

Summary

The global radioligand therapy market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors, including the rising incidence of various types of cancers and increasing awareness of alpha radioimmunotherapy, are propelling the growth of the market. Radioligand therapy is an advanced approach to treat certain kinds of cancer. It provides radiation to targeted cancer cells, with a negligible effect on healthy cells. This therapy provides life-enhancing treatment for patients with cancer who have inadequate therapeutic options. The other factors supporting the market’s growth are a growing world population, large patient pool, rising product innovation and development due to technological advancements, increasing government investments, increasing radioisotopes in healthcare, rising per capita healthcare expenditure, growing number of mergers and strategic acquisitions, and a large number of clinical trials.
Rising Incidence of Various types of Cancers
Cancer is a leading cause of death across the world. The growing prevalence of various types of cancers, especially prostate cancer and neuroendocrine tumors, is bolstering the growth of the market. According to the International Agency for Research on Cancer (IARC), in 2018, there were approximately 17.0 million new cancer cases and 9.5 million cancer-related deaths across the world. Prostate cancer and neuroendocrine tumors are the most common cancer, especially in American men. As per the American Cancer Society, in 2019, around 174,650 new cases of prostate cancer were detected in the U.S. Owing to the rise in the number of patients suffering from cancer, the surge in demand for radioligand therapy is driving the growth of the market.
Increased Awareness of Alpha Radioimmunotherapy and Rise in R&D Activities
Alpha Radioimmunotherapy is a targeted anti-tumor therapy that provides successful treatments. Therefore, the rise in awareness among people and physicians regarding alpha-radioimmunotherapy is bolstering the growth of the market. In addition, the rise in research & development of radioligand therapy to treat a wide range of cancer types is augmenting the global radioligand therapy market, globally. The advent of novel methods, such as lutetium 177, prostate-specific membrane antigen (PSMA), and others, for the treatment of cancer is due to continuous research and development activities. For instance, POINT Biopharma Global Inc. is planning to enter the market for radioligand therapy with the PNT2003 drug, which is presently in the last phases of clinical trials.
Increasing Investments and rising Initiatives by the Government
The rise in investments and various initiatives by governments to reduce the cancer burden is propelling the growth of the market. For instance, in 2021, the European Commission launched Europe’s Beating Cancer Plan, which aims to offer cancer services with a focus on disease prevention and early diagnosis. Later, in 2022, the European government intended to pour over $4.2 billion into cancer research and care.
Market Segmentation
The global radioligand therapy market is segmented into indication, product, biomarker, end user, and company. Based on indication, the market is divided into prostate cancer, neuroendocrine tumor, and others. Based on product, the market is divided into lutathera, zytiga, xtandi, and xofigo. Based on a biomarker, the market is divided into prostate-specific membrane antigen, Ki 67 expression and grading, and cytochrome P450 17A1 inhibitor. Based on end-user, the market is divided into biotechnology & pharmaceutical companies, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising cases of prostate cancer in the country.
Market Players
Novartis International, AG, Johnson & Johnson, Pfizer, Inc., Amneal Pharmaceuticals LLC., POINT Biopharma Global Inc, Fusion Pharmaceuticals Inc., Clovis Oncology, Inc., Telix Pharmaceuticals Limited, Lantheus Holdings, Inc., Progenics Pharmaceuticals, and Bayer AG are some of the leading companies operating in the market.
Report Scope:
In this report, global radioligand therapy market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
• Radioligand Therapy Market, By Indication:
o Prostate Cancer
o Neuroendocrine Tumor
o Others
• Radioligand Therapy Market, By Product:
o Lutathera
o Zytiga
o Xtandi
o Xofigo
• Radioligand Therapy Market, By Biomarker:
o Prostate-Specific Membrane Antigen
o Ki 67 Expression and Grading
o Cytochrome P450 17A1 Inhibitor
• Radioligand Therapy Market, By End User:
o Biotechnology & Pharmaceutical Companies
o Academic & Research Institutions
o Others
• Radioligand Therapy Market, By Region:
o North America
 United States
 Canada
 Mexico
o Asia-Pacific
 China
 India
 Japan
 Australia
 South Korea
o Europe & CIS
 Germany
 France
 United Kingdom
 Spain
 Italy
o South America
 Brazil
 Argentina
 Colombia
o Middle East & Africa
 South Africa
 Saudi Arabia
 UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in Global Radioligand Therapy Market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る


Table of Contents

1. Product Overview
2. Research Methodology
3. Executive Summary
4. Impact of COVID-19 on Global Radioligand Therapy Market
5. Voice of Customer
6. Clinical Trial Analysis
7. Global Radioligand Therapy Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indication (Prostate Cancer, Neuroendocrine Tumor, Others)
7.2.2. By Product (Lutathera, Zytiga, Xtandi, Xofigo)
7.2.3. By Biomarker (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor)
7.2.4. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
7.2.5. By Region
7.2.6. By Company (2021)
7.3. Market Map
8. North America Radioligand Therapy Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indication
8.2.2. By Product
8.2.3. By Biomarker
8.2.4. By End User
8.2.5. By Country
8.3. North America: Country Analysis
8.3.1. United States Radioligand Therapy Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Indication
8.3.1.2.2. By Product
8.3.1.2.3. By Biomarker
8.3.1.2.4. By End User
8.3.2. Canada Radioligand Therapy Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Indication
8.3.2.2.2. By Product
8.3.2.2.3. By Biomarker
8.3.2.2.4. By End User
8.3.3. Mexico Radioligand Therapy Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Indication
8.3.3.2.2. By Product
8.3.3.2.3. By Biomarker
8.3.3.2.4. By End User
9. Europe Radioligand Therapy Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Indication
9.2.2. By Product
9.2.3. By Biomarker
9.2.4. By End User
9.2.5. By Country
9.3. Europe: Country Analysis
9.3.1. France Radioligand Therapy Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Indication
9.3.1.2.2. By Product
9.3.1.2.3. By Biomarker
9.3.1.2.4. By End User
9.3.2. Germany Radioligand Therapy Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Indication
9.3.2.2.2. By Product
9.3.2.2.3. By Biomarker
9.3.2.2.4. By End User
9.3.3. United Kingdom Radioligand Therapy Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Indication
9.3.3.2.2. By Product
9.3.3.2.3. By Biomarker
9.3.3.2.4. By End User
9.3.4. Italy Radioligand Therapy Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Indication
9.3.4.2.2. By Product
9.3.4.2.3. By Biomarker
9.3.4.2.4. By End User
9.3.5. Spain Radioligand Therapy Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Indication
9.3.5.2.2. By Product
9.3.5.2.3. By Biomarker
9.3.5.2.4. By End User
10. Asia-Pacific Radioligand Therapy Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Indication
10.2.2. By Product
10.2.3. By Biomarker
10.2.4. By End User
10.2.5. By Country
10.3. Asia-Pacific: Country Analysis
10.3.1. China Radioligand Therapy Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Indication
10.3.1.2.2. By Product
10.3.1.2.3. By Biomarker
10.3.1.2.4. By End User
10.3.2. India Radioligand Therapy Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Indication
10.3.2.2.2. By Product
10.3.2.2.3. By Biomarker
10.3.2.2.4. By End User
10.3.3. Japan Radioligand Therapy Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Indication
10.3.3.2.2. By Product
10.3.3.2.3. By Biomarker
10.3.3.2.4. By End User
10.3.4. South Korea Radioligand Therapy Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Indication
10.3.4.2.2. By Product
10.3.4.2.3. By Biomarker
10.3.4.2.4. By End User
10.3.5. Australia Radioligand Therapy Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Indication
10.3.5.2.2. By Product
10.3.5.2.3. By Biomarker
10.3.5.2.4. By End User
11. South America Radioligand Therapy Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Indication
11.2.2. By Product
11.2.3. By Biomarker
11.2.4. By End User
11.2.5. By Country
11.3. South America: Country Analysis
11.3.1. Brazil Radioligand Therapy Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Indication
11.3.1.2.2. By Product
11.3.1.2.3. By Biomarker
11.3.1.2.4. By End User
11.3.2. Argentina Radioligand Therapy Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Indication
11.3.2.2.2. By Product
11.3.2.2.3. By Biomarker
11.3.2.2.4. By End User
11.3.3. Colombia Radioligand Therapy Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Indication
11.3.3.2.2. By Product
11.3.3.2.3. By Biomarker
11.3.3.2.4. By End User
12. Middle East and Africa Radioligand Therapy Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Indication
12.2.2. By Product
12.2.3. By Biomarker
12.2.4. By End User
12.2.5. By Country
12.3. MEA: Country Analysis
12.3.1. South Africa Radioligand Therapy Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1. By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1. By Indication
12.3.1.2.2. By Product
12.3.1.2.3. By Biomarker
12.3.1.2.4. By End User
12.3.2. Saudi Arabia Radioligand Therapy Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1. By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1. By Indication
12.3.2.2.2. By Product
12.3.2.2.3. By Biomarker
12.3.2.2.4. By End User
12.3.3. UAE Radioligand Therapy Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1. By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1. By Indication
12.3.3.2.2. By Product
12.3.3.2.3. By Biomarker
12.3.3.2.4. By End User
13. Market Dynamics
13.1. Drivers
13.2. Challenges
14. Market Trends & Developments
15. Competitive Landscape (Inclusive SWOT Analysis)
15.1. Novartis International, AG
15.2. Johnson & Johnson
15.3. Pfizer, Inc.
15.4. Amneal Pharmaceuticals LLC.
15.5. POINT Biopharma Global Inc
15.6. Fusion Pharmaceuticals Inc.
15.7. Clovis Oncology, Inc.
15.8. Telix Pharmaceuticals Limited
15.9. Lantheus Holdings, Inc.
15.10. Progenics Pharmaceuticals
15.11. Bayer AG
16. Strategic Recommendations

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

TechSci Research社のヘルスケア分野での最新刊レポート

本レポートと同じKEY WORD(industry)の最新刊レポート


よくあるご質問


TechSci Research社はどのような調査会社ですか?


テックサイリサーチ(TechSci Research)は、カナダ、英国、インドに拠点を持ち、化学、IT、環境、消費財と小売、自動車、エネルギーと発電の市場など、多様な産業や地域を対象とした調査・出版活... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/12/23 10:26

157.72 円

164.94 円

201.11 円

ページTOPに戻る